PatientsVille.com Logo

PRODUCT QUALITY ISSUE and Mirtazapine

PatientsVille

PRODUCT QUALITY ISSUE Symptoms and Causes

We all need clean water. People need it to grow crops and to operate factories, and for drinking and recreation. Fish and wildlife depend on it to survive.

Many different pollutants can harm our rivers, streams, lakes, and oceans. The three most common are soil, nutrients, and bacteria. Rain washes soil into streams and rivers. The soil can kill tiny animals and fish eggs. It can clog the gills of fish and block light, causing plants to die. Nutrients, often from fertilizers, cause problems in lakes, ponds, and reservoirs. Nitrogen and phosphorus make algae grow and can turn water green. Bacteria, often from sewage spills, can pollute fresh or salt water.

You can help protect your water supply:

  • Don't pour household products such as cleansers, beauty products, medicines, auto fluids, paint, and lawn care products down the drain. Take them to a hazardous waste collection site.
  • Throw away excess household grease (meat fats, lard, cooking oil, shortening, butter, margarine, etc.) diapers, condoms, and personal hygiene products in the garbage can.
  • Clean up after your pets. Pet waste contains nutrients and germs.

Environmental Protection Agency

Check out the latest treatments for PRODUCT QUALITY ISSUE

PRODUCT QUALITY ISSUE treatment research studies

Mirtazapine clinical trials, surveys and public health registries


Find Drug Side Effect reports



Mirtazapine Side Effects

Completed Suicide (237)
Confusional State (206)
Hyponatraemia (180)
Depression (160)
Overdose (148)
Anxiety (147)
Fall (136)
Dizziness (130)
Agitation (130)
Condition Aggravated (123)
Somnolence (117)
Insomnia (113)
Headache (110)
Serotonin Syndrome (109)
Suicidal Ideation (107)
Fatigue (105)
Loss Of Consciousness (104)
Convulsion (103)
Aggression (103)
Suicide Attempt (100)
Nausea (96)
Oedema Peripheral (93)
Dyspnoea (92)
Weight Increased (90)
Tachycardia (90)
Tremor (84)
Malaise (82)
Vomiting (75)
Restless Legs Syndrome (75)
Myalgia (73)
Alanine Aminotransferase Increased (72)
Cardiac Arrest (71)
Inappropriate Antidiuretic Hormone Secretion (71)
Feeling Abnormal (70)
Toxicity To Various Agents (69)
Asthenia (69)
Diarrhoea (67)
Syncope (62)
Hyperhidrosis (61)
Neuroleptic Malignant Syndrome (61)
Pain In Extremity (61)
Electrocardiogram Qt Prolonged (60)
Pyrexia (59)
Aspartate Aminotransferase Increased (58)
Pulmonary Embolism (57)
Arthralgia (56)
Hypotension (56)
Irritability (56)
Pain (55)
Gait Disturbance (54)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

i have been on citalopram and amatripolineand fluxaitne i have been on 15mg of mirtazapine and tryed 30mg the doc has put me on 45mg and i asked if these tablets dont work what is next hes said shrink as i have tryed all the ones he said but i have

My symptoms were tired, weak, unable to sleep. Was prescribed half of a 15 MG Mirtazapine nightly to help me sleep. Has this drug been successful used as a sleeping aid?

The above comment is too stupid, I actually LOLed at you Pete... lol you gave it 2 days and your complaining about the side-effects? and on 15 mgs? LMAO!!! It takes couple weeks at least to cope with the side-effects; just like m

48 year old male, I have suffered depression all my life. Have used SSRI's for the last ten years with good but mixed results. Last year lost my job due to an episode where I ended up throwing my monitor across the office and have not been able to wo

After a nasty experience with citalapram i was advised by my doc to try mirtazapine and it has suitedme very well. only side effect i canreport is an appetite increase. However as i don't carry much weight that isnt a problem.&

Back pain

Been on 90mg mirtazapine for 6 years twice the recomended dose is this considered safe

Body covered in hives

Does mirtazapine have muscles side effects?

Hi, I have been on mittazapine for 10 days, sleepy , tierd all the time and slugish in response to conversation just horrid feel gastly , head ace, The worst went to bed 11pm took the 15mg pill, went to the loo at 3am and collapse

Dear Sir/Madam, We are 'Alispo International' from Sialkot Pakistan. As a manufacturer, we supply 'SURGICAL DENTAL HAND INSTRUMENTS' in high quality, including Gynecology, ENT, Ophthalmic, Cardiac, Orthodontic and endodontic instruments. O

i never had an issue with using theraflu before. this time around i feel drunk every time i take it. i feel really super drowsy. and it is not working at all. i am still very congested even though i have a runny nose. i am still sore all over even t

>:o Took my first dose today,it left me covered in a red itchy rash on neck,chest,back and sides within 10 minutes of consuming.This product is now sitting in the trash can. :(

Hey Michelle, we almost have the same issue..I switched from Yaz to Trinessa because I and my husband thought it caused my severe mood swings prior to my period. I have been running and working out but I start experiencing joint

<span style='color: #808080;'><b>Describe Your Nystagmus from DTAP + IPV + HIB (PENTACEL) 2010 Experience Here: My duagters very first set of vaccination shots at 3 months caused nystagmus. We did not notice the issue

'OCAS' means that the product is administered over a time period. For this reason it must be swallowed whole and not chewed.

....however, dalacine is very effective unto face. kaya ngaun patuloy na ang paggamit ko sa product na ito.. try niyo rin para masubukan niyo. sabi nga hindi mo malalaman ang tamis hangat hindi mo nasusubukan ang pa.it....jejejeje' &nb

1.2-methyl-2-butene is treated with the following reagents write the structural formula of the mian organic product in each case

According to unspsc classification ,in which commodity this product fall?

After i use sensordyne , i have extremely pain travel from the back of my throat and uperjaw to my head . I though this product will reduce sensitivity in my teeth , now i have more pain then before.

PRODUCT QUALITY ISSUE Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Unknown  Evaluation of Mirtazapine and Folic Acid for Schizophrenia:
Conditions: Schizophrenia;   Negative Symptoms
Interventions: Drug: Mirtazapine and folic acid;   Drug: Mirtazapine, folic acid placebo;   Drug: Mirtazapine placebo, folic acid;   Drug: Mirtazapine placebo, folic acid placebo
Outcome Measures: To compare the efficacy of Mirtazapine and placebo for treatment of symptoms associated with schizophrenia;   To compare the efficacy of folic acid and placebo for treatment of symptoms of schizophrenia;   To compare the efficacy of Mirtazapine and placebo for treatment of negative symptoms of schizophrenia;   To compare the efficacy of folic acid and placebo for treatment of negative symptoms of schizophrenia;   To compare the safety and tolerability of Mirtazapine and placebo in patients with schizophrenia;   To compare the safety and tolerability of folic acid and placebo in patients with schizophrenia
2 Recruiting Effectiveness Study of Mirtazapine Combined With Paroxetine in Major Depressive Patients Without Early Improvement
Condition: Major Depression
Interventions: Drug: Mirtazapine, paroxetine;   Drug: Mirtazapine;   Drug: paroxetine 20mg QD
Outcome Measures: Change of 17-item Hamilton Depression Scale (HAMD-17) total score;   The proportion of subjects at endpoint with HAMD-17≤7;   The incidence and nature of overall adverse events;   The incidence and nature of drug-related adverse events;   The number of subject withdrawal due to adverse events during double-blind phase
3 Recruiting Pharmacogenetic Study of Mirtazapine Response in Depressed Patients
Condition: Depression
Intervention: Drug: Mirtazapine
Outcome Measures: Mirtazapine response at 2,4,6 weeks and adverse events (A/E) monitoring at 1,2,4,6 weeks;   Biological value at 0 and 6 weeks
4 Unknown  Mirtazapine Versus Placebo in Functional Dyspepsia
Condition: Functional Dyspepsia
Intervention: Drug: Mirtazapine
Outcome Measures: Difference in dyspepsia symptom scores week 8 versus week 0;   Individual symptom severities;   Nepean dyspepsia index for quality of life in functional dyspepsia
5 Recruiting Mirtazapine Plus Gemcitabine Versus Gemcitabine in Metastasis Pancreatic Cancer
Condition: Pancreatic Cancer
Interventions: Drug: Mirtazapine plus gemcitabine;   Drug: Gemcitabine, placebo
Outcome Measures: quality of life;   anxiety and depression scores;   objective response rate;   progress free survival,;   overall Survival;   chemotherapy induced nausea and vomiting
6 Recruiting Mirtazapine for Sleep Disorders in Alzheimer's Disease
Conditions: Alzheimer's Disease;   Sleep Disorders
Intervention: Drug: Mirtazapine
Outcome Measures: Change From Baseline in Nighttime Total Sleep Time;   Change From Baseline in Nighttime Number Of Awakenings;   Change From Baseline in Nighttime Wake After Sleep Onset;   Change From Baseline in in Daytime Total Sleep Time;   Change From Baseline in Number of Daytime Naps;   Change in Cognitive Function (as Measured by the Mini-Mental State Examination);   Change in Activities of Daily Living (The Index of ADL - Katz);   Change of Baseline in Behavioral Variables (BAHAVE-AD Scale);   Change From Baseline in Cognitive Function (Digit Symbol Substitution Test)
7 Recruiting LEPR Polymorphism Weight Gain by Mirtazapine in Late Life Depression
Condition: Major Depressive Disorder
Intervention: Drug: Mirtazapine
Outcome Measures: increase in weight as measured in the clinic;   Proportion of population achieving clinical response as measured by rate of fall in HAM-D 24 item scores;   Proportion of patients achieving remission at end of study on HAM-D 24 (<11);   Frequency of adverse events;   Percentage adhering to medication
8 Recruiting Efficacy Study of Mirtazapine to Treat Interferon-related Depression During Antiviral Therapy for Hepatitis C
Condition: Depression
Interventions: Drug: Mirtazapine;   Other: Supportive psychotherapy
Outcome Measures: Change from baseline in Hamilton Depression Rating Scale (HAMD)-17 at 8 weeks;   Change from baseline in quality of life at 8 weeks;   Genetic polymorphism
9 Recruiting Mirtazapine for the Treatment of Methamphetamine Dependence Among MSM (M2.0)
Condition: Methamphetamine
Interventions: Drug: Mirtazapine;   Drug: Placebo
Outcome Measures: Number of methamphetamine-positive urine tests;   Sexual risk (see description)
10 Recruiting Mirtazapine Treatment of Anxiety in Children and Adolescents With Pervasive Developmental Disorders
Condition: Autism Spectrum Disorders
Interventions: Drug: Placebo;   Drug: Mirtazapine
Outcome Measures: Pediatric Anxiety Rating Scale (PARS);   Clinical Global Impressions (CGI)
11 Unknown  Hippocampal Volume in Young Patients With Major Depression Before and After Combined Antidepressive Therapy
Condition: Depressive Disorder, Major
Interventions: Drug: Mirtazapine;   Drug: Venlafaxine
Outcome Measures: Categorial response to the medication. Categorial response is defined on the basis of CGI Improvement scale and 50% reduction in MADR-S score;   Tolerability of treatment as assessed using the DOTES scale;   Cognitive deficits as judged by the SKT system;   Self assessment of depression and anxiety using Beck's Depression/Anxiety Inventory (BDI/BAI);   Changes is blood levels of homocysteine, folate, vit B12, P11
12 Recruiting Algorithm Guided Treatment Strategies for Major Depressive Disorder
Condition: Major Depressive Disorder
Interventions: Drug: Escitalopram;   Drug: Mirtazapine;   Other: modified electroconvulsive therapy;   Other: repetitive transcranial magnetic stimulation;   Drug: Fluoxetine;   Drug: Citalopram;   Drug: Paroxetine;   Drug: Sertraline;   Drug: Fluvoxamine;   Drug: Venlafaxine;   Drug: Duloxetine;   Drug: Bupropion;   Drug: Trazodone
Outcome Measures: Remission defined as endpoint 17-item Hamilton Rating Scale for Depression (HRSD-17) total score ≤ 7;   Remission defined as endpoint the Quick Inventory of Depressive Symptomatology (16-item) (QIDS-SR16) total score ≤ 5;   Frequency and intensity of adverse events;   Quality of life
13 Unknown  Study of Methylphenidate as Add on Therapy in Depressed Cancer Patients
Condition: Depression
Interventions: Drug: Methylphenidate;   Drug: Placebo
Outcome Measures: depressive symptoms;   Distress level
14 Recruiting Strategic Use of New Generation Antidepressants for Depression
Condition: Unipolar Major Depressive Episode
Interventions: Drug: Sertraline;   Drug: Mirtazapine
Outcome Measures: Observer-rated depression severity (PHQ-9);   Self-rated depression severity (BDI-II);   Global rating of side effects (FIBSER)
15 Recruiting Predict Antidepressant Responsiveness Using Pharmacogenomics
Conditions: Depression;   Depressive Symptoms
Interventions: Drug: SSRI class antidepressant;   Drug: non-SSRI class antidepressant
Outcome Measure: Presences of each individual symptom of depression at 1,2,4,6,12 weeks
16 Recruiting Pharmacogenomic Study to Predict Antidepressant Responsiveness in Depressed Patients
Conditions: Depression;   Adverse Reaction to Drug
Interventions: Drug: SSRI class antidepressant;   Drug: non-SSRI class antidepressant
Outcome Measures: Antidepressant Response at 2,4,6 weeks A/E monitoring at 1,2,4,6 weeks;   Biological value at 0 and 6 weeks
17 Recruiting Development of Pharmacogenomic Method to Predict Antidepressant Responsiveness
Conditions: Depression;   Antidepressant Drug Adverse Reaction
Interventions: Drug: SSRI class antidepressant;   Drug: non-SSRI class antidepressant
Outcome Measures: all pharmacogenetic and biological marker variables cause drug response;   all clinical cause drug response
18 Recruiting Interpersonal Psychotherapy for Treatment Resistant Depression
Condition: Treatment Resistant Depression
Interventions: Other: IPT+ antidepressant drugs;   Drug: fluoxetine;   Drug: sertraline;   Drug: paroxetine;   Drug: Citalopram;   Drug: escitalopram;   Drug: fluvoxamine;   Drug: Venlafaxine;   Drug: Duloxetine;   Drug: Bupropion;   Drug: Lithium;   Drug: Risperidone;   Drug: tranylcypromine;   Drug: Imipramine;   Drug: amitriptyline;   Drug: Clomipramine;   Drug: nortriptyline;   Drug: trazodone;   Drug: Mirtazapine;   Drug: sulpiride
Outcome Measures: Hamilton Depression Scale (HAM-D) - continuous;   Beck depression Inventory (BDI)
19 Recruiting Study Comparing 3 Different Treatments for Arthritis of the Lower Back (Lumbar Spinal Stenosis)
Condition: Lumbar Spinal Stenosis
Interventions: Drug: NSAIDs; adjunctive analgesics; adjunctive anti-depressants;   Procedure: Lumbar epidural injection;   Other: Joint Mobilizations (spine, sacroiliac, hip);   Other: Individualized exercises: clinical setting;   Other: Group Exercise: community setting
Outcome Measures: Swiss Spinal Stenosis Questionnaire Score;   Self Paced Walking Test
20 Unknown  Continuation Electroconvulsive Therapy (C-ECT) for Relapse Prevention in Major Depression
Condition: Depression
Interventions: Device: Thrymatron System IV device (CONSOLIDATION ELECTROCONVUsLIVE THERAPY) plus PHARMACOTHERAPY;   Drug: PHARMACOTHERAPY
Outcome Measures: Hamilton Depression Rating Scale 21 items (HDRS-21);   Mini-Mental State Examination (MMSE 35);   UKU - Adverse effects rating scales;   Demographical Data Memory (MEDABI-20);   Rey Figure;   Trail Making Test A;   Trail Making Test B;   Stroop Test;   Direct and inverse digits (WAIS, Weschler Adults Intelligence Sacle).;   Vocabulary WAIS (Weschler Adults Intelligence Scale);   Frequency Hospitalization Quotient;   Hospital Day Quotient (HDQ)